Picture of Eckert & Ziegler SE logo

EUZ — Eckert & Ziegler SE News Story

0.000.00%
de flag iconLast trade - 00:00
HealthcareAdventurousMid CapFalling Star

Germany's Eckert & Ziegler H1 net income rises, confirms FY view

Germany's Eckert & Ziegler H1 net income rises, confirms FY view


Overview

  • Germany isotope components maker's H1 sales were flat yr/yr, adjusted EBIT declined nearly 6%

  • Net income for H1 rose about 5% to €22.4 mln

  • Company confirmed 2026 sales and EBIT guidance


Outlook

  • Eckert & Ziegler confirms 2026 sales forecast of around €320 mln

  • Company maintains 2026 EBIT before special items guidance at around €80 mln


Result Drivers

  • LICENSING REVENUE IMPACT - Co said group sales and earnings rose 4% and 9% respectively when excluding prior-year extraordinary licensing revenue, which was absent in 2026

  • MEDICAL SEGMENT GROWTH - Adjusted EBIT in Medical segment rose nearly 7% to €24.9 mln, with sales slightly above prior-year level; pharmaceutical radioisotopes remained key revenue driver

  • ISOTOPE PRODUCTS STABLE - Isotope Products segment sales were nearly unchanged yr/yr at €68.5 mln


Company press release: ID:nEQ5rHbCKa


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

H1 Sales

EUR 149.30 mln

H1 EPS

EUR 0.36

H1 Net Income

EUR 22.40 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

  • Wall Street's median 12-month price target for Eckert & Ziegler SE is €21.00, about 52.7% above its August 12 closing price of €13.75

  • The stock recently traded at 16 times the next 12-month earnings vs. a P/E of 18 three months ago


Reuters Recommended Reads

  • Aug 12 - Germany's Medios H1 profit hit by pricing pressure; to buy 74% of Caelo to expand API

  • Aug 11 - Germany's Dermapharm prelim H1 revenue rises, maintains outlook

  • Aug 12 - Sweden's Magle Chemoswed Q2 revenue rises on improved production efficiencies


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Eckert & Ziegler SE

See all news